key: cord-0742855-yi0h76dj
authors: Hay, J. A.; Kennedy-Shaffer, L.; Mina, M. J.
title: Viral loads observed under competing strain dynamics
date: 2021-07-30
journal: nan
DOI: 10.1101/2021.07.27.21261224
sha: 9dd6d1b41e52a1eee6fd7c7b035872c874651382
doc_id: 742855
cord_uid: yi0h76dj

A plausible mechanism for the increased transmissibility of SARS-CoV-2 variants of concern (VOCs) results from VOC infections causing higher viral loads in infected hosts. However, investigating this hypothesis using routine RT-qPCR testing data is challenging because the population-distribution of viral loads changes depending on the epidemic growth rate; lower cycle threshold (Ct) values for a VOC lineage may simply reflect increasing incidence relative to preexisting lineages. To understand the extent to which viral loads observed under routine surveillance systems reflect viral kinetics or population dynamics, we used a mathematical model of competing strain dynamics and simulated Ct values for variants with different viral kinetics. We found that comparisons of Ct values obtained under random cross-sectional surveillance were highly biased unless samples were obtained at times when the variants had comparable growth rates. Conversely, comparing Ct values from symptom-based testing was largely unaffected by epidemic dynamics, and accounting for the time between symptom onset and sample collection date further reduced the risk of statistical errors. Finally, we show how a single cross-sectional sample of Ct values can be used to jointly estimate differences in viral kinetics and epidemic growth rates between variants. Epidemic dynamics should be accounted for when investigating strain-specific viral kinetics using virologic surveillance data, and findings should be corroborated with longitudinal viral kinetics studies.

One of the biggest threats to combating the SARS-CoV-2 pandemic, or indeed any virologic 31 epidemic, is the emergence of novel variants that may be harder to control or exhibit increased 32 disease severity [1] [2] [3] [4] . Variants with increased growth rates, which may arise through 33 mutations affecting infectivity or antigenicity, can quickly come to dominate existing lineages 34 and generate new waves of infection [5] [6] [7] [8] [9] [10] [11] . Whereas existing non-pharmaceutical 35 interventions and population immunity may be sufficient to suppress existing viruses, they may 36 be insufficient for more transmissible variants, threatening the robustness of vaccine-induced 37 herd immunity and exacerbating problems in settings with limited access to vaccines. 38

Identifying measurable properties of variants that indicate increased transmission potential is 39 therefore essential for controlling the SARS-CoV-2 pandemic, as in the case of seasonal 40 influenza [12] [13] [14] . 41 A hypothesized mechanism for increased transmissibility relates to improved within-host 42 replication, which may result in higher viral loads [15] [16] [17] . If viral load predicts infectivity 43 [17, 18, 19] , then infections with new variants that elicit higher peak viral load, shorter 44 incubation periods or slower clearance rates could be more transmissible and for a longer 45 period of time. Testing this hypothesis would ideally rely on longitudinal viral kinetics studies 46 to directly compare viral loads over the course of infection [16, 20, 21] . However, such data are 47 rare, and comparisons of viral loads have therefore typically been done using routinely 48 collected RT-qPCR surveillance data from asymptomatic or symptomatic individuals [5, 22] . 49

Indeed, multiple such studies have now proposed that samples isolated from variant of 50 concern (VOC) infections demonstrate higher viral loads than from non-VOC infections [22-51 26] . 52 However, comparisons of viral loads, usually proxied using RT-qPCR cycle threshold (Ct) 53 values, from surveillance samples are potentially biased depending on the epidemiological 54 context [27] [28] [29] . It has been shown that cycle threshold (Ct) values observed through 55 population-level surveillance are expected to change depending on the underlying epidemic 56 growth rate: Ct values are skewed lower when the epidemic is growing due to the abundance 57 of recent infections, and skewed higher when the epidemic is growing due to the 58 predominance of older infections [27, 30] . Comparing Ct values from different lineages which 59 may have different growth rates at the time of sample collection therefore has the potential for 60 bias. Higher viral loads from VOC samples may simply reflect a growing epidemic as opposed 61

to higher peak or more sustained viral loads, making it difficult to accurately infer differences 62

Modeling framework to compare viral loads arising in a two-strain epidemic 78

We developed a mathematical model to simulate viral loads, observed as RT-qPCR Ct values, 79 in a population undergoing a two-strain epidemic ( Figure 1 ). We implemented a two-strain 80 SEIR model to simulate incidence curves under a scenario where a more transmissible variant 81 (referred to as the "new variant") is introduced into the population and outcompetes a 82 preexisting, less transmissible lineage (referred to as the "original variant"). We assumed that 83 these strains have identical epidemiological parameters other than their basic reproductive 84 numbers, and that infection elicits symmetric cross-protection against the other variant. We 85 combined these incidence curves ( Figure 1A ) with the viral kinetics models shown in Figure Ct values from samples obtained under random cross-sectional surveillance at a single point 104 in time will reflect differences arising both from epidemic dynamics, which dictate the recency 105 of infection, as well as underlying viral kinetics ( Figure 1D ). When simulated samples were 106 obtained in this way and the new variant samples were compared to the original variant 107 samples using a Wilcoxon rank-sum test with significance level of 5%, we found that type 1 108 statistical errors occurred in 25% of simulations when using 25 detectable Ct values from each 109 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21261224 doi: medRxiv preprint of the two variants, increasing to nearly 100% when comparing 500 detectable Ct values 110 ( Figure S1 ). 111

One approach to overcome these statistical biases and accurately detect underlying 112 differences in viral kinetics is to compare samples taken from time points of comparable growth 113 rates ( Figure 2A 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 30, 2021. using the same time-since-infection model in Figure 1C but assumed that individuals were 148 sampled after some delay following the onset of symptoms. We assumed that symptomatic 149 individuals have incubation periods drawn from a log-normal distribution with median 5.0 days 150 and variance of 5.8 days, and are subsequently sampled after some delay drawn from a 151 discretized gamma distribution with shape and scale parameters of 5 and 1 respectively 152 ( Figure 3A ). This corresponds to a mean confirmation delay of 4.5 days and variance of 5.1 153 days following symptom onset. Both variants were assumed to have the same incubation 154 period and sampling delay distribution. In addition, on the individual level, the Ct value at any 155 day was independent of the incubation period length and sampling delay. We note that the 156 choice of these distribution parameters is arbitrary; similar patterns will be observed with 157 different values. 158

Although some differences remained in observed Ct values over time between the two 159 variants, the difference was small unless the new variant had truly different underlying viral 160 kinetics ( Figure 3B ). This is because the time-since-infection distributions for the two strains 161 are comparable regardless of the underlying growth rate, as individuals are always sampled 162 at a similar time post onset and therefore post infection ( Figure 3C ). Therefore, comparing Ct 163 values between variants obtained from symptomatic surveillance largely reflects true 164 differences in underlying viral kinetics ( Figure 3D ). 165

However, statistical comparisons may still lead to flawed conclusions if the time-since-onset 166 and sampling delay distributions are substantially different between the two variants. Even 167 when the same distributions are assumed, some small difference in the observed time-since-168 infection distribution will arise due to differences in the underlying epidemic growth rate (see 169 Figure S3 and S4 from [27] for further details). For example, if an epidemic is growing, then 170 individuals with symptom onset on a given day are more likely to have been recently infected 171 with a short incubation period simply due to the abundance of recent infections. Our 172 simulations show that as the number of samples being compared increases, the probability of 173 encountering a type 1 statistical error when using the Wilcoxon rank sum test increases. This 174 is true because of the reduced variation within groups, even though the between-variant 175 estimated median Ct difference is the same ( Figure S4 ). 176 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21261224 doi: medRxiv preprint

Using a linear regression model and including days-since-onset as an explanatory variable 177 drastically reduces the frequency of type 1 errors ( Figure S5 ). Indeed, accounting for days-178 since-onset becomes vital when the distribution of delays between symptom onset and 179 sampling differs between the two variants. Figure S6 shows type 1 statistical errors are almost 180 guaranteed when using a Wilcoxon rank sum test if the original variant has a different sampling 181 delay distribution (assuming shape and scale parameters of 7 and 0.9 as opposed to 5 and 182 1), but Figure S7 shows that these errors can be drastically reduced through using a 183 regression model accounting for days-since-onset. We note that type 1 errors still arise at 184 large sample sizes, as accounting for days-since-onset only partially accounts for the small 185 differences in the time-since-infection distribution (i.e., it does not account for the incubation 186 period). 187

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 30, 2021.

values 202

Finally, we approached the system from a different perspective: rather than testing for 203 differences in viral kinetics between variants based on surveillance samples, we asked if we 204 could use random cross-sectional samples taken from the same point in time to infer 205 differences in variant-specific growth rates. Again, we generated a synthetic population of 206 SARS-CoV-2 infections by simulating Ct values obtained through random cross-sectional 207 surveillance at a single point in time assuming that the variants had different viral kinetics (as 208 shown in Figure 1B) . We then adapted a previously described method to estimate the growth 209 in frequency ( Figure 4A ), we were generally able to accurately re-estimate the true growth 216 rates of the two variants ( Figure 4B ). The model was also able to quantify the true difference 217 in peak viral loads elicited by the new variant ( Figure 4C ); however, it was not able to identify 218 the slower clearance rate. Similarly, in the scenario when infections from both variants were 219 simultaneously increasing but at different rates ( Figure 4D ), we were able to identify that the 220 new variant likely had a higher growth rate, although not unequivocally based on the 95% 221 credible intervals (CrI) on the difference in growth rate ( Figure 4E ). Again, differences in peak 222 Ct value were identifiable, but not in the clearance rate ( Figure 4F ). These results show that 223 although lower median Ct values may be explained either by higher growth rates or differences 224 in viral kinetics, the full distribution of Ct values may hold information that allows both 225 processes to be identified. 226

The results shown in Figure 4 are from a single simulation of detectable Ct values. Therefore, 227 to explore the identifiability of these differences in growth rates and viral kinetics based on CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21261224 doi: medRxiv preprint growth rate even with 500 Ct values per variant. This appeared to be largely driven by the lack 236 of precision in growth rate estimates for the original variant, resulting in wide credible intervals. 237

Nonetheless, posterior mean estimates were consistently identified as different between the 238 two variants. Differences in peak Ct value were also identifiable in both epidemiologic 239 scenarios with as few as 25 Ct values; however, even at 500 Ct values per variant, we were 240 unable to reliably identify the true difference in viral clearance rates (Figures S10 and S11). 241

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21261224 doi: medRxiv preprint 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21261224 doi: medRxiv preprint

Given the relationship between epidemic growth rate and the distribution of viral loads in a 256 population [27], care must be taken when directly comparing viral loads between variants 257 using surveillance samples to avoid drawing incorrect conclusions of differences in strain 258 virulence. Infections from variants with positive growth rates will typically be more recent than 259 infections from co-circulating variants with negative growth rates, resulting in higher average 260 viral loads. These findings provide a conceptually similar caution to analyses assessing the 261 association between mutations and transmissibility [14,31]: just as mutations may be 262 associated with increased growth rates simply due to founder effects or chance, infections 263 with new variants may be associated with increased viral loads simply because they are 264 experiencing higher epidemic growth rates. 265

We found that comparing Ct values between variants using samples obtained entirely at 266 random from the population are far more likely to lead to incorrect conclusions regarding 267 differences in underlying viral kinetics than samples obtained from recently symptomatic 268 individuals. This is because of how these sampling strategies reflect the underlying time-since- is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21261224 doi: medRxiv preprint for the delay between symptom onset and sample collection, the significance of this 289 relationship was lost, similar to our simulation results [5] . Another analysis comparing Ct 290 values between two variants in Washington State, USA also initially performed a direct 291 comparison of Ct values between a variant with a 614G substitution [22] . Again, the authors 292 found that 614G was associated with lower Ct values than 614D. In contrast to the analysis 293 by [5], this significant difference in Ct value remained after accounting for a number of potential 294 confounders such as days after symptom onset and patient age. In this study, epidemic 295 dynamics were likely not important in dictating Ct value distributions, as Ct values did not 296 appear to be associated with time of sample collection and the time-since-onset distribution 297 was similar between the two variants. 298

Although epidemic dynamics have the potential to bias viral load comparisons, particularly 299 using random cross-sectional samples, many study designs are unlikely to be affected. 300

Comparing samples from recently symptomatic individuals, particularly when the distribution 301 of delays between symptom onset and sample collection date are similar between the variants 302 or are included in a regression model, is likely to lead to reliable conclusions. Such 303 comparisons will be even more reliable if the timing of symptom onset is dependent on viral 304 load (i.e., symptom onset occurs as a result of viral loads reaching their peak as opposed to 305 independently). It is worth noting that differences in sampling delay distributions will likely vary 306 independently of the epidemic growth rate simply due to the logistics of sample collection, 307 limitations on testing capacity and changes in policy dictating who is tested. Accounting for 308 time-since-onset is therefore advisable regardless. Other instances where epidemic dynamics Finally, we adapted a previous method, which is ultimately a generalized linear regression 333 model, to use Ct values obtained from a single point in time to simultaneously estimate 334 differences in growth rates alongside differences in viral kinetics [27] . In reality, these two 335 mechanisms may not be uniquely identifiable; however, understanding the combination of viral 336 kinetics and transmissibility differences that can explain the data may still be valuable to detect 337 variants of concern early and to quantify transmission advantages. This approach may be 338 particularly useful in settings where sequencing capacity is limited, as sequencing-339 independent means of stratifying samples by lineage (e.g., variant-specific primers, single 340 gene failure etc.) can be used to then compare Ct values between variants [43]. However, we 341 emphasize that this approach currently requires samples obtained through random cross-342 sectional surveillance, or nearly random samples such as non-COVID patient hospital testing. 343

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21261224 doi: medRxiv preprint

We used a deterministic, two-strain, susceptible-exposed-infected-recovered (SEIR) model to 346 simulate incidence curves for two competing strains in a fully susceptible population [44] . We 347 assumed that two strains were seeded in the population: an "original variant" with 0 = 1.5, 348 and a "new variant" with 0 = 2.5. The "original variant" was seeded on day 0 of the simulation, 349 and the "new variant" was either seeded on day 180 or on day 0 as specified in the Results. 350

We assumed that both strains had a 3-day mean latent period and 7-day mean infectious 351 period, and that individuals became permanently immune to the strain they were infected with 352 upon recovery. We also assumed that infection with one strain elicited strong cross-immunity 353 (75% reduced infection probability) to the other. Overall, this is a simplified implementation of 354 the model presented by [44] with no seasonality, no waning immunity and no births or deaths. Table S1 . 359 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. 

Using the simulated random cross-sectional samples of detectable Ct values, we jointly 436 estimated the posterior distributions of viral kinetics parameters and the exponential growth 437 rate that are consistent with the observed data. We repeated this process for each of the 100 438 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. with an unknown growth rate parameter; (2) defining priors for all model parameters as 443 described in Table S2; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21261224 doi: medRxiv preprint

Shown below are the ordinary differential equations for the two-strain susceptible-exposed- here, where | < ≤ + 7| indicates that exposed individuals are generated at rate 21 within a 7-day window following seeding. Parameters are described in Table S1 . Note that 22 0 = .

23 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21261224 doi: medRxiv preprint

To generate complete line lists for the simulated data underpinning Figure S5 and Figure 

) and scale parameter ( + ). All > are set to .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted July 30, 2021. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21261224 doi: medRxiv preprint 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21261224 doi: medRxiv preprint 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted July 30, 2021. ; https://doi.org/10.1101/2021.07.27.21261224 doi: medRxiv preprint

New SARS-CoV-2 Variants -Clinical, Public Health, 464 and Vaccine Implications

Dynamics and selection of many-strain pathogens

Global circulation 468 patterns of seasonal influenza viruses vary with antigenic drift

The global 471 circulation of seasonal influenza A (H3N2) viruses

Genomics 473 and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus

Increased mortality in community-tested cases of SARS-CoV-2 477 lineage B.1.1.7

Threat Assessment Brief: Implications for the EU/EEA on the spread of the SARS-CoV-479

617.2) variant of concern

Assessing 486 transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

488 Emergence and rapid spread of a new severe acute respiratory syndrome-related 489 coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa

Genomic characterization and Epidemiology of an emerging SARS-CoV-2 variant in 493

Predictive 495 Modeling of Influenza Shows the Promise of Applied Evolutionary Biology

SARS-CoV-2 variants, spike mutations and immune escape